Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

CLSD Insider Trading

Clearside Biomedical, Inc. | Pharmaceutical Preparations

Comprehensive Trading Performance Summary

The investment history of corporate insiders at Clearside Biomedical, Inc. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Pharmaceutical Preparations sector.

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2018-06-05 03:31 2018-06-04 White Daniel H. Director, Officer - President and CEO BUY $9.07 11,000 $99,770 483,335 +2.3%
2018-05-21 23:05 2018-05-17 Thorp Clay Director, 10% owner SELL $13.08 161,139 $2,107,585 3,466,394 -4.4%
2018-03-27 00:21 2018-03-23 Deignan Charles A. Officer - Chief Financial Officer BUY $11.79 500 $5,895 66,356 +0.8%
2018-03-24 00:51 2018-03-21 Thorp Clay Director, 10% owner SELL $12.21 138,861 $1,695,784 3,627,533 -3.7%
2018-03-23 16:17 2018-03-22 Cagle Gerald D. Director BUY $11.89 7,500 $89,175 23,441 +47.0%
2017-12-08 01:10 2017-12-05 Thorp Clay Director, 10% owner SELL $6.22 35,000 $217,550 3,766,394 -0.9%
2017-11-17 01:41 2017-11-14 Thorp Clay Director, 10% owner SELL $7.00 35,000 $245,102 3,801,394 -0.9%
2017-10-23 15:08 2017-10-18 White Daniel H. Director, Officer - President and CEO SELL $7.82 8,000 $62,520 35,309 -18.5%
2017-10-06 02:35 2017-10-03 Thorp Clay Director, 10% owner SELL $8.57 35,000 $299,901 3,836,394 -0.9%
2017-09-16 00:08 2017-09-13 Thorp Clay Director, 10% owner SELL $7.52 24,500 $184,186 3,871,394 -0.6%
2017-09-11 23:05 2017-09-07 White Daniel H. Director, Officer - President and CEO SELL $7.57 16,000 $121,080 36,109 -30.7%
2017-08-16 15:24 2017-08-15 SHAFFER CHRISTY L Director BUY $7.00 1,100 $7,700 4,400 +33.3%
2017-08-16 00:40 2017-08-11 Cagle Gerald D. Director BUY $7.08 5,000 $35,400 15,941 +45.7%
2017-08-15 00:01 2017-08-14 Deignan Charles A. Officer - Chief Financial Officer BUY $7.07 1,000 $7,065 65,309 +1.6%
2017-08-10 00:48 2017-08-07 Thorp Clay Director, 10% owner SELL $7.57 24,500 $185,490 3,895,894 -0.6%
2017-07-21 23:43 2017-07-19 White Daniel H. Director, Officer - President and CEO SELL $9.75 8,000 $78,000 37,709 -17.5%
2017-06-15 02:54 2017-06-13 White Daniel H. Director, Officer - President and CEO SELL $7.89 8,000 $63,080 38,509 -17.2%
2017-05-23 23:04 2017-05-22 SHAFFER CHRISTY L Director BUY $8.00 1,100 $8,800 3,300 +50.0%
2017-05-20 01:11 2017-05-18 Thorp Clay Director, 10% owner SELL $8.36 24,000 $200,611 3,920,394 -0.6%
2017-05-20 00:32 2017-05-17 White Daniel H. Director, Officer - President and CEO SELL $8.41 8,000 $67,280 39,309 -16.9%
2017-05-18 02:43 2017-05-15 Thorp Clay Director, 10% owner SELL $8.63 44,485 $384,097 3,944,394 -1.1%
2017-05-02 01:37 2017-03-27 Cagle Gerald D. Director BUY $7.10 14,064 $99,854 14,064 +100.0%
2017-04-20 03:12 2017-04-17 Thorp Clay Director, 10% owner SELL $7.46 68,485 $510,946 3,988,879 -1.7%
2017-04-06 00:24 2017-04-03 White Daniel H. Director, Officer - President and CEO SELL $7.55 8,000 $60,400 40,109 -16.6%
2017-03-23 00:14 2017-03-20 SHAFFER CHRISTY L Director BUY $6.90 2,200 $15,180 2,200 +100.0%
2017-03-21 00:23 2017-03-16 Cagle Gerald D. Director BUY $6.84 5,000 $34,200 10,941 +84.2%
2017-03-17 23:19 2017-03-15 Thorp Clay Director, 10% owner SELL $6.56 68,485 $449,542 4,057,364 -1.7%
2017-02-23 00:36 2017-02-21 Thorp Clay Director, 10% owner SELL $7.55 27,000 $203,731 4,125,849 -0.7%
2017-02-18 03:32 2017-02-15 Thorp Clay Director, 10% owner SELL $7.60 41,485 $315,103 4,152,849 -1.0%
2017-01-21 04:19 2017-01-17 Thorp Clay Director, 10% owner SELL $8.53 68,485 $583,999 4,194,334 -1.6%
2017-01-20 03:31 2017-01-17 Hatteras Venture Advisors IV SBIC, LLC 10% owner, Other SELL $8.63 29,656 $255,786 2,060,514 -1.4%
2017-01-20 01:53 2017-01-17 Hatteras Venture Advisors III, LLC 10% owner, Other SELL $8.63 25,301 $218,221 1,757,719 -1.4%
2016-06-07 23:42 2016-06-07 Cagle Gerald D. Director SELL $7.00 2 $14 5,941 0.0%
2016-06-07 23:41 2016-06-07 Deignan Charles A. Officer - Chief Financial Officer SELL $7.00 2 $14 62,759 0.0%
2016-06-07 23:41 2016-06-07 White Daniel H. Director, Officer - President and CEO SELL $7.00 3 $21 530,817 0.0%
2016-06-07 23:40 2016-06-07 RMI Investments S.a.r.l. 10% owner BUY $7.00 42,857 $299,999 1,558,024 +2.8%
2016-06-07 23:31 2016-06-07 Thorp Clay Director, 10% owner BUY $7.00 785,714 $5,499,998 4,262,819 +22.6%
2016-06-07 23:31 2016-06-07 Thorp Clay Director, 10% owner SELL $7.00 138 $966 3,477,105 0.0%
2016-06-07 23:38 2016-06-07 Hatteras Venture Advisors III, LLC 10% owner BUY $7.00 107,142 $749,994 1,783,020 +6.4%
2016-06-07 23:38 2016-06-07 Hatteras Venture Advisors III, LLC 10% owner SELL $7.00 69 $483 1,675,878 0.0%
2016-06-07 23:35 2016-06-07 Hatteras Venture Advisors IV SBIC, LLC 10% owner BUY $7.00 414,286 $2,900,002 2,090,170 +24.7%
2016-06-07 23:35 2016-06-07 Hatteras Venture Advisors IV SBIC, LLC 10% owner SELL $7.00 69 $483 1,675,884 0.0%
SHOW ENTRIES

How to Interpret $CLSD Trades

Not every insider transaction in Clearside Biomedical, Inc. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $CLSD shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for CLSD

Insider activity data for Clearside Biomedical, Inc. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $CLSD, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.